Results 111 to 120 of about 49,034 (223)
Chirality, Volume 38, Issue 4, April 2026.A design of experiments–based chiral HPLC method was developed for the enantiomeric separation and quantification of talazoparib in pharmaceutical formulations. Efficient resolution of the enantiomers (RS > 7) was achieved within 12 min. The method was validated and successfully applied to tablet analysis, and its environmental sustainability was ...
Sakine Atila Karaca +2 more
wiley +1 more source
DEN Open, Volume 6, Issue 1, April 2026.Abstract Objectives This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22‐gauge needle (22G) through endoscopic ultrasound‐guided fine needle acquisition (EUS‐TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical ...
Tami Nagatani +11 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims Colorectal cancer (CRC) is a serious global health problem, ranking first in men and third in women among all cancers worldwide. The genetic basis for CRC remains unclear in most cases; therefore, the present study aimed to investigate the molecular genetic basis of CRC and correlate it with disease outcomes.
Mahmood Rasool +10 more
wiley +1 more source
International Journal of Cancer, Volume 158, Issue 7, Page 1927-1940, 1 April 2026.What's new? Endocrine drugs repurposed from treatment protocols are the primary medications available for breast cancer (BC) prevention in at‐risk women. Adverse effects, however, significantly minimize uptake and prevention impact. Here, the authors investigated licochalcone A (LicA), a non‐endocrine anti‐inflammatory agent with reported hematologic ...
Atieh Hajirahimkhan +14 more
wiley +1 more source
MedComm, Volume 7, Issue 4, April 2026.This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang +9 more
wiley +1 more source
MedComm, Volume 7, Issue 4, April 2026.This study identifies C1orf35 as a key driver of colorectal cancer progression through a dual mechanism. It promotes tumor‐intrinsic cell proliferation and migration via the c‐Myc/PYCR2 axis, and suppresses anti‐tumor immunity by impairing CD8+ T‐cell immune surveillance, nominating it as a novel therapeutic target in colorectal cancer.
Shaosen Zhang +6 more
wiley +1 more source
Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 4, Page 568-574, April 2026.It is expected that the relugolix estetrol combination RE4W will enable women to control their fertility and prevent menstrual cycle related problems, while offering a smooth transition through perimenopause into the postmenopause and decrease the risk of breast cancer.
Herjan J. T. Coelingh Bennink +9 more
wiley +1 more source
British Journal of Pharmacology, Volume 183, Issue 8, Page 1709-1724, April 2026.Abstract Background and Purpose Gene regulation is frequently altered in diseases in unique and patient‐specific ways. Hence, personalised strategies have been proposed to infer patient‐specific gene‐regulatory networks. However, existing methods do not scale well because they often require recomputing the entire network per sample.
Johannes Kersting +5 more
wiley +1 more source
Health Expectations, Volume 29, Issue 2, April 2026.ABSTRACT Introduction Practitioners currently lack guidance on how to evaluate the potential negative impacts of biorepository research on communities. We set out to create a product for researchers and oversight boards that would assist them in ‘doing right’ by communities as they conduct this research.
Shauntey Kalweit +8 more
wiley +1 more source